Rexahn Announces Proposed Public Offering of Common Stock and Warrants
22 Janeiro 2019 - 7:42PM
Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) today announced
that it intends to offer and sell shares of its common stock and
warrants to purchase shares of its common stock in an underwritten
public offering. The offering is subject to market conditions and
there can be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the offering.
Oppenheimer & Co. Inc. is acting as sole
book-running manager for the offering.
Rexahn intends to use the net proceeds of the
offering for further development of its lead clinical programs,
including the funding of its clinical development programs for
RX-3117 and RX-5902, and for working capital and general corporate
purposes.
The securities described above are being offered
by the Company pursuant to a shelf registration statement on Form
S-3 (No. 333-218285) previously filed with and declared effective
by the Securities and Exchange Commission (SEC).
The securities will be offered by means of a
prospectus supplement and accompanying prospectus, forming a part
of the effective registration statement. A preliminary prospectus
supplement and the accompanying prospectus relating to and
describing the terms of the offering will be filed with the SEC and
will be available on the SEC’s website at http://www.sec.gov.
Copies of the final prospectus supplement, when available, and
accompanying prospectus may be obtained from Oppenheimer & Co.
Inc., Attention: Syndicate Prospectus Department, 85 Broad Street,
26th Floor, New York, New York 10004, by telephone at (212)
667-8055, or by email at EquityProspectus@opco.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy any of the
securities described herein, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals Inc. (NYSE American: RNN)
is a clinical stage biopharmaceutical company developing innovative
therapies to improve patient outcomes in cancers that are difficult
to treat. The Company’s mission is to improve the lives of cancer
patients by developing next-generation cancer therapies that are
designed to maximize efficacy while minimizing the toxicity and
side effects traditionally associated with cancer treatment.
Rexahn’s product candidates work by targeting and neutralizing
specific proteins believed to be involved in the complex biological
cascade that leads to cancer cell growth. Preclinical studies show
that several of Rexahn’s product candidates may be effective
against multiple types of cancer, including drug resistant cancers,
and difficult-to-treat cancers, and others may augment the
effectiveness of current FDA-approved cancer treatments. The
Company has two oncology product candidates, RX-3117 and RX-5902,
in Phase 2 clinical development and additional compounds in
preclinical development, including RX-0301. For more information
about the Company and its oncology programs, please visit
www.rexahn.com.
Safe Harbor
To the extent any statements made in this press
release deal with information that is not historical, these are
forward-looking statements under the Private Securities Litigation
Reform Act of 1995. Such statements include, but are not limited
to, statements regarding the timing and success of the proposed
offering, as well as the anticipated use of proceeds for the
proposed offering and other statements identified by words such as
“will,” “potential,” “could,” “can,” “believe,” “intends,”
“continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,”
other words of similar meaning or the use of future dates.
Forward-looking statements by their nature address matters that
are, to different degrees, uncertain. Uncertainties and risks may
cause Rexahn’s actual results to be materially different than those
expressed in or implied by Rexahn’s forward-looking statements. For
Rexahn, this includes satisfaction of the conditions to closing of
the offering, delays in obtaining required stock exchange or other
regulatory approvals, stock price volatility and the impact of
general business and economic conditions. More detailed information
on these and additional factors that could affect Rexahn’s actual
results are described in Rexahn’s filings with the Securities and
Exchange Commission, including its most recent annual report on
Form 10-K and subsequent quarterly reports on Form 10-Q. All
forward-looking statements in this news release speak only as of
the date of this news release. Rexahn undertakes no obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events or otherwise.
Media Contact: DGI Comm Susan
Forman or Laura Radocaj +1-212-825-3210 sforman@dgicomm.com
lradocaj@dgicomm.com
Investor Contact:
ir@rexahn.com
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024